Ulcerative colitis High Cost Drugs pathway
Crohn’s Disease High Cost Drugs pathway
Supply disruption of oral ranitidine: Statement for NCL Trusts
Supply disruption of oral ranitidine: Statement for Primary Care
The documents below have been agreed by the stakeholders working in North Central London and have been approved by the NCL Joint Formulary Committee (NCL JFC). They should be used to refer appropriate patients to his/her local anticoagulation clinic for initiation of anticoagulation.
Where appropriate, local anticoagulation clinics should add their own contact details on the relevant paperwork (i.e. referral proformas, notification and transfer of care forms)
Please note that these documents may be updated intermittently. Users are also reminded that the prescribing guidance is not definitive and that other sources such as the electronic medicines compendium (SPCs) should be used for the most recent drug information. This can be found at the following link: http://www.medicines.org.uk/emc/default.aspx
Summary of Antiplatelet Options in Cardiovascular Disease
Sacubitril valsartan for heart failure position statement (NEL and NCL joint positioning)
Statin prescribing & lipid modification guideline
Stable angina prescribing guideline
Omega-3 Fatty Acids Position Statement
Guidance for the review of Omega-3 fatty acids
Guidance for the management of hypertriglyceridaemia
The following COPD guideline has been produced by the Camden, Haringey and Islington Responsible Respiratory Prescribing Group and applies to organisations that are constituent members. It has not been ratified by the NCL Joint Formulary Committee and does not apply to all organisations in NCL.
NICE and Public Health England (PHE) have brought together their information on managing common infections into a summary table.
The North Central London Medicines Optimisation Committee (NCL MOC) agreed to remove their localised ‘Management and treatment of common infection’ guidance and support the use of the NICE Managing Common Infections summary table.
Antihyperglycaemic agents for Type 2 diabetes
Insulin for Type 2 diabetes
Blood glucose and Ketone monitoring
See ‘Flash glucose monitoring‘ page
Different CCGs across London and Hertfordshire have implemented Libre differently; to identify which CCG is responsible for a given patient, enter the patient’s registered GP practice name or postcode into https://openprescribing.net/practice/
| Region | Eligibility | Blueteq form | Hospital prescribing | Libre reimbursement for Trusts | Supporting paperwork |
|---|---|---|---|---|---|
| North Central London (Camden, Barnet, Enfield, Haringey, Islington CCGs) | LDCN/LPP criteria (v2) | Yes (initiation and continuation) | First 2 months only | Yes | Patient-prescriber agreement |
| North West London (Brent, Central [Westminster], Ealing, Hammersmith and Fulham, Harrow, Hillingdon, Hounslow, West [London Borough of Kensington and Chelsea and Queen’s Park and Paddington]) | NHS England criteria | Yes (initiation [inc. existing self-funders]) | First 2 months only | No | Patient-prescriber agreement GP request for acute prescribing (2-4 months) GP request for repeat prescribing (long-term) |
| North East London (Newham, Tower Hamlets, Waltham Forest, Barking and Dagenham, Havering, Redbridge, City and Hackney) | N,TH,WF: LDCN/LPP criteria B&D,H,R: LDCN/LPP criteria C&H: LDCN/LPP criteria | WF only: In progress Others: No | First 2 months only | No | Patient-prescriber agreement Request for short term prescribing Request for long-term prescribing |
| South East London (Bexley, Bromley, Greenwich, Lambeth, Lewisham, Southwark CCGs) | LDCN/LPP criteria (v2) | No | First 6 weeks only | Yes | GP request for short-term prescribing (6-9 months) GP request for long-term prescribing |
| South West London (Croydon, Kingston, Wandsworth, Richmond, Sutton, Merton) | LDCN/LPP criteria | No | First 2 months only | No | Patient-prescriber agreement Request for short term prescribing Request for long-term prescribing |
| Hertfordshire (Herts Valleys, East & North Herts CCGs) | NHS England criteria | Yes (initiation and continuation at 6 months) | First 6 months only | Yes | Patient-prescriber agreement (adults) Patient-prescriber agreement (paeds) GP notification of initiation (not a request to supply) GP request for long-term prescribing GP notification of discontinuation |
See ‘Cardiovascular‘
Low Molecular Weight Heparin (LMWH) prescribing guideline
Oral Nutritional Supplement Formulary in Adults – Primary Care Guidance
Calcium + vitamin D (CaVitD) supplements for prevention of osteoporotic fragility fractures guideline
Vitamin D deficiency in adults with low bone mineral density guideline
Rheumatoid arthritis biologic pathway
Bisphosphonate treatment duration in women position statement
Summary of MHRA alerts for bisphosphonates and denosumab
Glucosamine & Chondroitin Supplements Position Statement
Rubefacients Position Statement